To date, PPARγ agonists (rosiglitazone and pioglitazone) have been shown to increase insulin sensitivity and responsiveness, correct hyperglycemia, hyperinsulinemia, and hypertriglyceridemia in type 2 diabetes mellitus (DM2) patients, enhance adipocyte differentiation, and increase the mRNA expression of insulin-responsive glucose transporter 4 (GLUT4) in DM2 muscle tissue [12]. Here, PPARG is linked to type 2 diabetes mellitus.